Gritstone bio

Last updated

Gritstone bio was a clinical-stage American biotechnology company which attempted to develop cancer and infectious disease immunotherapies and vaccines. It was founded in August 2015 as Gritstone Oncology, Inc., with offices in Emeryville, California.

In September 2021 it raised $55.0 million from the sale of 5,000,000 shares. [1]

It started a Phase 1 trial of its self-amplifying mRNA second generation SARS-CoV-2 vaccine, GRT-R910, in the NIHCR Manchester Clinical Research Facility at Manchester Royal Infirmary, in September 2021. [2] This is to explore the ability of GRT-R910 to boost and expand the immunogenicity of AstraZeneca's first-generation COVID-19 vaccine AZD1222 (Vaxzevria) in healthy adults of more than 60 years. It uses lipid nanoparticles to deliver a broad set of antigens against SARS-CoV-2 that includes both stabilized spike protein and highly conserved viral protein regions containing T cell epitopes. [3] Prof. Andrew Ustianowski is the study’s chief investigator. [4]

On 10 November 2021, Gritstone announced positive preclinical data of its second-generation self-amplifying mRNA (SAM) vaccine against SARS-CoV-2 in non-human primate models. [5]

It is involved in a Phase 1/2 study, in collaboration with Bristol Myers Squibb, in 26 patients with metastatic solid tumors. [6]

In October 2024, Gritstone filed for Chapter 11 bankruptcy protection in efforts to move forward with its "strategic alternatives process". The company is looking for a stalking-horse bid that would allow for the company to continue operating.

On December 31, 2024, Andrew Allen, M.D., Ph.D., co-founder, President, and Chief Executive Officer of Gritstone Bio, stepped down from his role following the company's asset sale. Dr. Allen's departure, along with other key executives, marked a significant shift in Gritstone Bio's leadership. The resignations included:

Matthew Hawryluk, Ph.D., Executive Vice President and Chief Business Officer Erin E. Jones, Executive Vice President and Chief Operating Officer Karin Jooss, Ph.D., Executive Vice President and Head of Research and Development In the interim, Vassiliki “Celia” Economides assumed the role of Chief Executive Officer while maintaining her position as Chief Financial Officer, with no changes to her compensation.


Related Research Articles

<span class="mw-page-title-main">Arcturus Therapeutics</span> American biotech firm

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

mRNA vaccine Type of vaccine

An mRNAvaccine is a type of vaccine that uses a copy of a molecule called messenger RNA (mRNA) to produce an immune response. The vaccine delivers molecules of antigen-encoding mRNA into cells, which use the designed mRNA as a blueprint to build foreign protein that would normally be produced by a pathogen or by a cancer cell. These protein molecules stimulate an adaptive immune response that teaches the body to identify and destroy the corresponding pathogen or cancer cells. The mRNA is delivered by a co-formulation of the RNA encapsulated in lipid nanoparticles that protect the RNA strands and help their absorption into the cells.

<span class="mw-page-title-main">BioNTech</span> German biotechnology company

BioNTech SE is a global biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.

<span class="mw-page-title-main">Inovio COVID-19 vaccine</span> COVID-19 vaccine candidate

Inovio COVID-19 vaccine is a COVID-19 vaccine candidate developed by Inovio Pharmaceuticals.

<span class="mw-page-title-main">ARCT-021</span> Vaccine candidate against COVID-19

ARCT-021, also known as LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.

<span class="mw-page-title-main">PTX-COVID19-B</span> Vaccine candidate against SARS-CoV-2 (COVID-19)

PTX-COVID19-B is a messenger RNA (mRNA)-based COVID-19 vaccine, a vaccine for the prevention of the COVID-19 disease caused by an infection of the SARS-CoV-2 coronavirus, created by Providence Therapeutics—a private Canadian drug company co-founded by Calgary, Alberta-based businessman Brad T. Sorenson and San Francisco–based Eric Marcusson in 2013. A team of eighteen working out of Sunnybrook Research Institute in Toronto, Ontario developed PTX-COVID19-B in less than four weeks, according to the Calgary Herald. Human trials with sixty volunteers began on January 26, 2021, in Toronto.

<span class="mw-page-title-main">Sanofi–GSK COVID-19 vaccine</span> Protein subunit vaccine against COVID-19

The Sanofi–GSK COVID-19 vaccine, sold under the brand name VidPrevtyn Beta, is a COVID-19 vaccine developed by Sanofi Pasteur and GSK.

iNCOVACC Vaccine candidate against COVID-19

iNCOVACC is an intranasal COVID-19 vaccine candidate developed by Bharat Biotech, American company Precision Virologics and the Washington University School of Medicine in St Louis, Missouri, United States.

<span class="mw-page-title-main">UB-612</span> Vaccine candidate against COVID-19

UB-612 is a COVID-19 vaccine candidate developed by United Biomedical Asia, and Vaxxinity, Inc. It is a peptide vaccine.

<span class="mw-page-title-main">Walvax COVID-19 vaccine</span> Vaccine candidate against COVID-19

AWcorna, originally termed ARCoV and also known as the Walvax COVID-19 vaccine, is an mRNA COVID-19 vaccine developed by Walvax Biotechnology, Suzhou Abogen Biosciences, and the PLA Academy of Military Science. In contrast to other mRNA COVID-19 vaccines, such as those by Pfizer-BioNTech and Moderna, this vaccine primarily targets the SARS-CoV-2 receptor-binding domain of the spike protein, rather than the entire spike protein. It is approved for Phase III trials in China, Mexico, Indonesia, and Nepal.

<span class="mw-page-title-main">V-01</span> Vaccine candidate against COVID-19

V-01 is a protein subunit COVID-19 vaccine candidate developed by a subsidiary of Livzon Pharmaceutical Group Inc.

<span class="mw-page-title-main">Razi Cov Pars</span> Vaccine candidate against COVID-19

Razi Cov Pars is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute Razi Cov Pars is a covid-19 vaccine based on recombinant protein, which is being produced by Razi Vaccine and Serum Research Institute, Iran. This vaccine is the first injectable-intranasal recombinant protein corona vaccine.It's the second Iranian COVID-19 vaccine reaching human trials and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine.

mRNA-1283 Vaccine candidate against COVID-19

mRNA-1283 is a COVID-19 vaccine candidate developed by Moderna.

<span class="mw-page-title-main">ARCT-154</span> Vaccine candidate against COVID-19

ARCT-154, also known as VBC-COV19-154 in Vietnam, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics. For its development, Arcturus collaborated with Vinbiocare, a Vietnamese company, for support with clinical trials and manufacturing. The vaccine was authorised in Japan in November 2023.

<span class="mw-page-title-main">AdCLD-CoV19</span> Vaccine candidate against COVID-19

AdCLD-CoV19 is a COVID-19 vaccine candidate developed by Cellid Co, a company from South Korea.

<span class="mw-page-title-main">COVID-19 vaccine clinical research</span> Clinical research to establish the characteristics of COVID-19 vaccines

COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness, and safety. As of November 2022, 40 vaccines are authorized by at least one national regulatory authority for public use:

<span class="mw-page-title-main">Noora (vaccine)</span> Vaccine candidate against COVID-19

Noora is a COVID-19 vaccine candidate developed by Baqiyatallah University of Medical Sciences in collaboration with Plasma Darman Sarv Sepid Co. in Iran. Introduced in June 2021, it was announced as having "successfully passed the first phase of its clinical trial" two months later.

Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.

<span class="mw-page-title-main">S-268019</span> Vaccine candidate against COVID-19

S-268019-b is a protein subunit COVID-19 vaccine candidate developed by Shionogi.

<span class="mw-page-title-main">ABNCoV2</span> Vaccine candidate against COVID-19

ABNCoV2 is a cVLP COVID-19 vaccine candidate developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic.

References

  1. ↑ "Gritstone Announces Private Placement Financing of $55.0 Million". Globe Newswire. 16 September 2021. Retrieved 22 September 2021.
  2. ↑ "Early trial of multivariant COVID-19 vaccine booster begins in Manchester". ManchesterUniversity. 20 September 2021. Retrieved 22 September 2021.
  3. ↑ "Gritstone Bio Doses First Volunteer In Phase 1 Trial Of GRT-R910 As COVID-19 Vaccine Booster". Nasdaq. 20 September 2021. Retrieved 22 September 2021.
  4. ↑ "Trial of first COVID-19 variant-proof jab begins in UK". Arab News. 21 September 2021. Retrieved 22 September 2021.
  5. ↑ "Gritstone Announces Positive Preclinical Data in Non-Human Primate Challenge Study with Second-Generation COVID-19 Vaccine Against SARS-CoV-2". GlobeNewswire News Room (Press release). 2021-11-10. Retrieved 2021-12-06.
  6. ↑ "Gritstone Announces Dosing of First Solid Tumor Patient with Optimized SLATE "Off-the-Shelf" Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial". Global Newswire. 17 September 2021. Retrieved 22 September 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.